Ellevest Inc. Sells 38,549 Shares of Takeda Pharmaceutical Company Limited (NYSE:TAK)

Ellevest Inc. cut its stake in Takeda Pharmaceutical Company Limited (NYSE:TAK) by 48.8% in the fourth quarter, Holdings Channel.com reports. The firm owned 40,379 shares of the company’s stock after selling 38,549 shares during the period. Ellevest Inc.’s holdings in Takeda Pharmaceutical were worth $535,000 as of its most recent filing with the Securities and Exchange Commission (SEC).

Several other hedge funds and other institutional investors also recently bought and sold shares of the stock. Wilmington Savings Fund Society FSB acquired a new stake in shares of Takeda Pharmaceutical during the 3rd quarter worth approximately $40,000. Farther Finance Advisors LLC lifted its position in Takeda Pharmaceutical by 123.6% in the fourth quarter. Farther Finance Advisors LLC now owns 3,575 shares of the company’s stock worth $47,000 after purchasing an additional 1,976 shares during the period. Crowley Wealth Management Inc. acquired a new stake in Takeda Pharmaceutical during the fourth quarter worth $52,000. Cromwell Holdings LLC bought a new stake in Takeda Pharmaceutical in the 4th quarter valued at $61,000. Finally, Venturi Wealth Management LLC raised its stake in shares of Takeda Pharmaceutical by 554.7% in the 4th quarter. Venturi Wealth Management LLC now owns 5,028 shares of the company’s stock valued at $67,000 after buying an additional 4,260 shares in the last quarter. 9.17% of the stock is currently owned by institutional investors and hedge funds.

Takeda Pharmaceutical Trading Up 0.6 %

Shares of TAK opened at $14.36 on Friday. The stock has a 50 day simple moving average of $14.87 and a 200-day simple moving average of $13.99. The company has a current ratio of 1.31, a quick ratio of 0.72 and a debt-to-equity ratio of 0.63. The stock has a market cap of $45.69 billion, a PE ratio of 35.90, a PEG ratio of 0.24 and a beta of 0.26. Takeda Pharmaceutical Company Limited has a 1 year low of $12.58 and a 1 year high of $15.43.

Takeda Pharmaceutical (NYSE:TAK) last issued its quarterly earnings data on Thursday, May 8th. The company reported $0.16 earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of $0.24 by ($0.08). Takeda Pharmaceutical had a net margin of 4.53% and a return on equity of 9.39%. The company had revenue of $7.34 billion for the quarter, compared to the consensus estimate of $8.02 billion. On average, sell-side analysts predict that Takeda Pharmaceutical Company Limited will post 1.64 EPS for the current fiscal year.

Wall Street Analyst Weigh In

Separately, Morgan Stanley raised shares of Takeda Pharmaceutical from an “equal weight” rating to an “overweight” rating in a research note on Wednesday, April 2nd.

Takeda Pharmaceutical Profile

Takeda Pharmaceutical Company Limited engages in the research, development, manufacture, marketing, and out-licensing of pharmaceutical products in Japan and internationally. It offers pharmaceutical products in the areas of gastroenterology, rare diseases, plasma derived therapies, immunology, oncology, and neuroscience.